Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 9/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24313862 | 0.92 | METTL3 (0.56) | METTL3PRMT5WDR77FLT3ADORA3 | |
| SCHEMBL29611085 | 0.92 | METTL3 (0.56) | METTL3PRMT5WDR77FLT3ADORA3 | |
| SCHEMBL24313566 | 0.90 | PRMT5 (0.58) | METTL3PRMT5WDR77FLT3 | |
| SCHEMBL29610857 | 0.83 | ADORA3 (0.43) | ADORA3ALDH1A1TSHR | |
| SCHEMBL29611653 | 0.83 | ADORA3 (0.43) | ADORA3ALDH1A1TSHR | |
| SCHEMBL24313565 | 0.83 | ADORA3 (0.43) | ADORA3ALDH1A1TSHR | |
| SCHEMBL24313864 | 0.83 | ADORA3 (0.43) | ADORA3ALDH1A1TSHR | |
| SCHEMBL29610818 | 0.82 | ADORA3 (0.40) | METTL3PRMT5WDR77ADORA3 | |
| SCHEMBL24313535 | 0.82 | ADORA3 (0.40) | METTL3PRMT5WDR77ADORA3 | |
| SCHEMBL24313513 | 0.79 | PRMT5 (0.45) | METTL3PRMT5WDR77FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS INC (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4229067-A1 | METTL3 MODULATORS | Accent Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081739-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081739-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | METTL3 1/4885PRMT5 78/4885WDR77 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.